QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events
… from today’s presentations include the following: Sepofarsen for CEP290 -mediated Leber congenital amaurosis 10 … of 36 patients aged 8 years or older to receive either sepofarsen at the target registration dose, a low dose, or …
… Quarter 2023 Operating and Financial Results Divestment of sepofarsen and ultevursen ophthalmic programs supports … we were very pleased to announce the divestment of our sepofarsen and ultevursen programs to Théa, where they will …
… Financial Results Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data … including completing enrollment in the pivotal trial of sepofarsen, reporting positive clinical data for QR-421a, and …
… Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 … of ProQR. “We completed enrollment in the pivotal trial of sepofarsen, reported positive clinical data for QR-421a, …
… Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late … in need. We continue to be on track for the readout of the sepofarsen Illuminate trial in the first half of next year …
… analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps … readout of top-line results from the Illuminate trial of sepofarsen, we are conducting a comprehensive analysis of the …
… 2023 Additional pivotal trial recommended by EMA for sepofarsen prior to a regulatory submission Company will seek … – including Illuminate , Insight , and Brighten for sepofarsen, along with Sirius and Helia for ultevursen – will …
… Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen … data from our InSight extension study supporting sepofarsen’s potential to treat patients with LCA10 and …